{
    "clinical_study": {
        "@rank": "88940", 
        "arm_group": [
            {
                "arm_group_label": "Natural cycle", 
                "arm_group_type": "Active Comparator", 
                "description": "Natural cycle endometrial biopsy, lh+7"
            }, 
            {
                "arm_group_label": "Antagonist cycle + endometrial priming.", 
                "arm_group_type": "Experimental", 
                "description": "Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5"
            }, 
            {
                "arm_group_label": "Agonist cycle + endometrial priming.", 
                "arm_group_type": "Experimental", 
                "description": "Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to analyse genomics profile expression in endometrium under\n      different endometrial priming for recipients."
        }, 
        "brief_title": "Endometrial Genomic Profile in Endometrial Priming", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": "Genomic Human Endometrial Expression Profile", 
        "detailed_description": {
            "textblock": "We analyze the genomic profile of egg donors in different endometrial priming protocols,\n      compared with natural cycle, including the conventional single long acting GnRH agonist\n      injection in the mid luteal phase of the previous cycle of the endometrial priming and the\n      single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular\n      phase followed by endometrial priming.  Endometrial biopsy will be taken in luteinizing\n      hormone\n\n        -  7 or with P4 +5 in cases with endometrial priming with oestrogens therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  6 egg healthy volunteer egg donors.\n\n          -  Volunteers.\n\n          -  18-35 years old\n\n          -  Healthy.\n\n          -  BMI <28.\n\n        Exclusion Criteria:\n\n          -  - BMI > 28\n\n          -  Smokers-"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01778452", 
            "org_study_id": "VLC18012013"
        }, 
        "intervention": {
            "arm_group_label": [
                "Natural cycle", 
                "Antagonist cycle + endometrial priming.", 
                "Agonist cycle + endometrial priming."
            ], 
            "description": "endometrial biopsy", 
            "intervention_name": "endometrial biopsy", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Endometrial priming, genomic expression. Natural cycle. Antagonist GnRH.", 
        "lastchanged_date": "February 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Valencia", 
                    "country": "Spain", 
                    "zip": "46015"
                }, 
                "name": "Ivi Valencia"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "3", 
        "official_title": "Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.", 
        "overall_official": {
            "affiliation": "IVI Valencia", 
            "last_name": "Carmen Vidal, MDphD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "implantation related genes profile expression", 
            "measure": "genetic endometrial human profile expression", 
            "safety_issue": "Yes", 
            "time_frame": "Oocyte donors will be followed up for four to six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01778452"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Instituto Valenciano de Infertilidad, Spain", 
        "sponsors": {
            "collaborator": {
                "agency": "Iviomics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Instituto Valenciano de Infertilidad, Spain", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}